Nuclear Medicine Market Research Report Information by Type (Diagnosis [SPECT Radiopharmaceuticals {Tc99m, I-123, and Others} and PET Radiopharmaceuticals {F18, C11 Choline, and Others}] and Therapeutic (Alpha Emitters [Actinium-225 (Ac-225), Radium-223 (

Nuclear Medicine Market Research Report Information by Type (Diagnosis [SPECT Radiopharmaceuticals {Tc99m, I-123, and Others} and PET Radiopharmaceuticals {F18, C11 Choline, and Others}] and Therapeutic (Alpha Emitters [Actinium-225 (Ac-225), Radium-223 (Ra-223), and Others], Beta Emitters [Yttrium-90 (Y-90), Lutetium-177 (Lu-177), and Others], and Brachytherapy Isotopes [Iodine-125 (I-125) and Others]), by Application (Neurology, Cardiology, Oncology [Prostate Cancer, Breast Cancer, Lung and Bronchus Cancer, Thyroid Cancer, Colorectal Cancer, and Others], and Others), by End User (Hospitals & Diagnostic Centers, Research Institutes, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) – Industry Forecast till 2032

In 2023, the nuclear medicine market was estimated at USD 9.84 billion. The nuclear medicine market is expected to expand from USD 10.63 billion in 2024 to USD 27.96 billion in 2032. Increased radioisotope uses in the healthcare industry, as well as technological improvements in nuclear medicine, are driving market expansion. Furthermore, rising public-private funding for new technique R&D, as well as increased R&D in the pharmaceutical and biotechnology industries to improve radiotherapy for proper diagnosis of diseases such as thyroid-related diseases, respiratory diseases, bone diseases, neurological diseases, and others, are driving the growth of the nuclear medicine market.


Market Segment insights
The Nuclear Medicine Market is divided into two categories: diagnostic and therapeutic. The Nuclear Medicine Market has been classified by application, including neurology, cardiology, cancer, and others. The Nuclear Medicine Market is divided into three segments based on the end user: hospitals and diagnostic centers, research institutes, and others.

Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America had the biggest market share of 42.42% in 2023, owing to the existence of active industry players in the region and the availability of products, which drove the market's growth in North America. Europe is expected to grow significantly during the forecast period due to an increasing number of people suffering from heart disease, Alzheimer's disease, and neurological problems, rising expenditure, and an increased demand for better diagnostic and treatment processes, all of which are driving growth in the European market. Furthermore, the nuclear medicine market is expanding because of better radiopharmaceuticals, new launches, acquisitions, and mergers. The market in Asia-Pacific is expected to grow fast because to an increase in cardiac patients and enhanced imaging techniques employing diagnostic equipment such as PET and SPECT. Furthermore, the ability to obtain multiple 2D and 3D pictures using SPECT imaging techniques, and a gamma camera improves access for physicians, which is propelling the region's nuclear medicine business forward. Furthermore, the Japanese nuclear medicine market had the biggest market share in 2023, while India's nuclear medicine market was the fastest expanding in the Asia-Pacific region.

Major Players
Key players in the Nuclear Medicine Market include Novartis AG (Switzerland), GE Healthcare (US), Cardinal Health (US), Eckert & Ziegler Group (Germany), Lantheus (US), Jubilant Radiopharma (Canada), Bayer AG (Germany), Siemens Healthineers (Germany), Curium Pharma (France), Bracco (Italy), and others.